BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Negro F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology 2014;61:S69-78. [DOI: 10.1016/j.jhep.2014.08.003] [Cited by in Crossref: 95] [Cited by in F6Publishing: 82] [Article Influence: 13.6] [Reference Citation Analysis]
Number Citing Articles
1 Enomoto H, Aizawa N, Hasegawa K, Ikeda N, Sakai Y, Yoh K, Takata R, Yuri Y, Kishino K, Shimono Y, Ishii N, Takashima T, Nishimura T, Nishikawa H, Iwata Y, Iijima H, Nishiguchi S. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients. Int J Mol Sci 2020;21:E3089. [PMID: 32349377 DOI: 10.3390/ijms21093089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Jung J, Du P, Feldman R, Riley T 3rd. Discontinuation of new hepatitis C drugs among Medicare patients. Am J Manag Care 2020;26:84-8. [PMID: 32059096 DOI: 10.37765/ajmc.2020.42397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Liu CY, Ko PH, Yen HR, Cheng CH, Li YH, Liao ZH, Hsu CH. The Chinese medicine Kuan-Sin-Yin improves liver function in patients with chronic hepatitis C: A randomised and placebo-controlled trial. Complement Ther Med 2016;27:114-22. [PMID: 27515885 DOI: 10.1016/j.ctim.2016.06.004] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cespiati A, Petta S, Lombardi R, Di Marco V, Calvaruso V, Bertelli C, Pisano G, Fatta E, Sigon G, Iuculano F, Crapanzano L, Gibilaro G, Francione P, Craxì A, Fargion S, Fracanzani AL. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). Dig Liver Dis 2020:S1590-8658(20)30997-X. [PMID: 33214063 DOI: 10.1016/j.dld.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Gong Y, Cun W. The Role of ApoE in HCV Infection and Comorbidity. Int J Mol Sci. 2019;20:pii: E2037. [PMID: 31027190 DOI: 10.3390/ijms20082037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Goossens N, Negro F. Cardiovascular Manifestations of Hepatitis C Virus. Clin Liver Dis 2017;21:465-73. [PMID: 28689586 DOI: 10.1016/j.cld.2017.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
7 Piekarska A, Mamzer-Dachnowska A, Kasprzak JD, Peruga JZ, Kaszuba A, Berkan-Kawińska A. Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls - PRO-CARDIO-C study. Clin Exp Hepatol 2019;5:118-22. [PMID: 31501787 DOI: 10.5114/ceh.2019.84782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Mada PK, Malus ME, Parvathaneni A, Chen B, Castano G, Adley S, Moore M, Hieda M, Alam MJ, Feldman M, King JW. Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus. Int J Hepatol 2020;2020:6438753. [PMID: 32395351 DOI: 10.1155/2020/6438753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kobayashi N, Iijima H, Tada T, Kumada T, Yoshida M, Aoki T, Nishimura T, Nakano C, Takata R, Yoh K, Ishii A, Takashima T, Sakai Y, Aizawa N, Nishikawa H, Ikeda N, Iwata Y, Enomoto H, Hirota S, Fujimoto J, Nishiguchi S. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Eur J Gastroenterol Hepatol 2018;30:546-51. [PMID: 29494353 DOI: 10.1097/MEG.0000000000001106] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
11 Stevenson HL, Utay NS. Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era. Trop Dis Travel Med Vaccines 2016;2:21. [PMID: 28883965 DOI: 10.1186/s40794-016-0038-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
12 Smolders EJ, Ter Horst PJG, Wolters S, Burger DM. Cardiovascular Risk Management and Hepatitis C: Combining Drugs. Clin Pharmacokinet 2019;58:565-92. [PMID: 30259390 DOI: 10.1007/s40262-018-0710-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
13 Meng Z, Liu Q, Sun F, Qiao L. Hepatitis C virus nonstructural protein 5A perturbs lipid metabolism by modulating AMPK/SREBP-1c signaling. Lipids Health Dis 2019;18:191. [PMID: 31684957 DOI: 10.1186/s12944-019-1136-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Ambrosino P, Tarantino L, Criscuolo L, Nasto A, Celentano A, Di Minno MN. The risk of venous thromboembolism in patients with hepatitis C: A systematic review and meta-analysis. Thromb Haemost 2017;116:958-66. [DOI: 10.1160/th16-03-0185] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 4.8] [Reference Citation Analysis]
15 Álvaro-Meca A, Jiménez-Sousa MA, Boyer A, Medrano J, Reulen H, Kneib T, Resino S. Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit. BMC Infect Dis 2016;16:122. [PMID: 26979964 DOI: 10.1186/s12879-016-1448-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
16 Modaresi Esfeh J, Ansari-Gilani K. Steatosis and hepatitis C. Gastroenterol Rep (Oxf) 2016;4:24-9. [PMID: 26276502 DOI: 10.1093/gastro/gov040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
17 Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol 2018;2018:6150861. [PMID: 30186821 DOI: 10.1155/2018/6150861] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
18 Ampuero J, Romero-Gómez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol. 2015;7:2214-2219. [PMID: 26380047 DOI: 10.4254/wjh.v7.i19.2214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
19 Wu A, Burrowes S, Zisman E, Brown TT, Bagchi S. Association of hepatitis C infection and acute coronary syndrome: A case-control study. Medicine (Baltimore) 2021;100:e26033. [PMID: 34032724 DOI: 10.1097/MD.0000000000026033] [Reference Citation Analysis]
20 Fabiani S, Fallahi P, Ferrari SM, Miccoli M, Antonelli A. Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature. Rev Endocr Metab Disord. 2018;19:405-420. [PMID: 29322398 DOI: 10.1007/s11154-017-9440-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 18.0] [Reference Citation Analysis]
21 Onyekwere CA, O Ogbera A, Olusola Dada A, O Adeleye O, O Dosunmu A, Akinbami AA, Osikomaiya B, Hameed O. Hepatitis C Virus (HCV) Prevalence in Special Populations and Associated Risk Factors: A Report From a Tertiary Hospital. Hepat Mon 2016;16:e35532. [PMID: 27313634 DOI: 10.5812/hepatmon.35532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
22 Kolb H, Martin S. Environmental/Lifestyle factors in the pathogenesis and prevention of type 2 diabetes. BMC Med. 2017;15:131. [PMID: 28720102 DOI: 10.1186/s12916-017-0901-x] [Cited by in Crossref: 152] [Cited by in F6Publishing: 107] [Article Influence: 38.0] [Reference Citation Analysis]
23 Cacciola I, Russo G, Filomia R, Pitrone C, Caccamo G, Giandalia A, Alibrandi A, Stella Franzè M, Porcari S, Maimone S, Saitta C, Squadrito G, Raimondo G. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. Liver Int 2021;41:2059-67. [PMID: 33894103 DOI: 10.1111/liv.14905] [Reference Citation Analysis]
24 Qvigstad C, Tait RC, Rauchensteiner S, Berntorp E, de Moerloose P, Schutgens RE, Holme PA; ADVANCE Working Group. The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment. Medicine (Baltimore) 2018;97:e12551. [PMID: 30278553 DOI: 10.1097/MD.0000000000012551] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Lévy P, Bartosch B. Metabolic reprogramming: a hallmark of viral oncogenesis. Oncogene 2016;35:4155-64. [DOI: 10.1038/onc.2015.479] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
26 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
27 Mingorance L, Castro V, Ávila-Pérez G, Calvo G, Rodriguez MJ, Carrascosa JL, Pérez-Del-Pulgar S, Forns X, Gastaminza P. Host phosphatidic acid phosphatase lipin1 is rate limiting for functional hepatitis C virus replicase complex formation. PLoS Pathog 2018;14:e1007284. [PMID: 30226904 DOI: 10.1371/journal.ppat.1007284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
28 Scudiero F, Valenti R, Marcucci R, Sanna GD, Gori AM, Migliorini A, Vitale R, Giusti B, De Vito E, Corda G, Paniccia R, Zirolia D, Canonico ME, Parodi G. Platelet Reactivity in Hepatitis C Virus-Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. J Am Heart Assoc 2020;9:e016441. [PMID: 32885738 DOI: 10.1161/JAHA.120.016441] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Cuciureanu T, Chiriac S, Chiorescu M, Gîrleanu I, Trifan A. Chronic hepatitis C virus infection: a new modifiable cardio-metabolic risk factor? Clujul Med 2017;90:251-5. [PMID: 28781519 DOI: 10.15386/cjmed-793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Liu Z, Que S, Zhou L, Zheng S, Romeo S, Mardinoglu A, Valenti L. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis. Sci Rep 2017;7:9273. [PMID: 28839198 DOI: 10.1038/s41598-017-09548-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
31 Cacoub P, Comarmond C. New insights into HCV-related rheumatologic disorders: A review. J Adv Res 2017;8:89-97. [PMID: 28149645 DOI: 10.1016/j.jare.2016.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
32 Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, Goto T, Wakahata A, Nakashima M, Nakamuta M, Tanaka J. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2018;47:1012-1022. [PMID: 29424449 DOI: 10.1111/apt.14554] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
33 Todorovska B, Joksimovic N, Caloska-Ivanova V, Dimitrova-Genadieva M, Trajkovska M, Curakova E, Kiprijanovska S, Zafirova-Ivanovska B, Serafimoski V. Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2017;38:25-33. [PMID: 28593897 DOI: 10.1515/prilozi-2017-0003] [Reference Citation Analysis]
34 Konno R, Tatebe S, Sugimura K, Satoh K, Aoki T, Miura M, Yamamoto S, Sato H, Kozu K, Terui Y, Miyata S, Adachi O, Kimura M, Saiki Y, Shimokawa H. Effects of Hepatitis C Virus Antibody-Positivity on Cardiac Function and Long-Term Prognosis in Patients With Adult Congenital Heart Disease. Am J Cardiol 2018;122:1965-71. [PMID: 30442226 DOI: 10.1016/j.amjcard.2018.08.045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
35 Cacoub P, Comarmond C. Considering hepatitis C virus infection as a systemic disease. Semin Dial 2019;32:99-107. [PMID: 30549107 DOI: 10.1111/sdi.12758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Jung J, Feldman R, Kalidindi Y, Riley T 3rd. Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries. JAMA Netw Open 2020;3:e208081. [PMID: 32602909 DOI: 10.1001/jamanetworkopen.2020.8081] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Strauhs-Nitsch L, Campiolo MF, Morsoletto DBG, Pissaia Junior A, Ivantes CAP. CURING HEPATITIS C WITH THE NEW DIRECT ACTING ANTIVIRALS DID NOT IMPROVE INSULIN RESISTANCE AFTER ONE YEAR. Arq Gastroenterol 2020;57:267-71. [PMID: 33027477 DOI: 10.1590/S0004-2803.202000000-50] [Reference Citation Analysis]
38 Yoshikawa A, Terashita K, Morikawa K, Matsuda S, Yamamura T, Sarashina K, Nakano S, Kobayashi Y, Sogabe S, Takahashi K, Haba S, Oda H, Takahashi T, Miyagishima T, Sakamoto N. Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report. Clin J Gastroenterol 2017;10:270-3. [PMID: 28447325 DOI: 10.1007/s12328-017-0742-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
39 Badawi A, Di Giuseppe G, Gupta A, Poirier A, Arora P. Bayesian network modelling study to identify factors influencing the risk of cardiovascular disease in Canadian adults with hepatitis C virus infection. BMJ Open 2020;10:e035867. [PMID: 32371519 DOI: 10.1136/bmjopen-2019-035867] [Reference Citation Analysis]
40 Chaudhury CS, Sheehan J, Chairez C, Akoth E, Gross C, Silk R, Kattakuzhy S, Rosenthal E, Kottilil S, Masur H. No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV. J Infect Dis. 2017;217:47-50. [PMID: 29161418 DOI: 10.1093/infdis/jix517] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
41 Babiker A, Hassan M, Muhammed S, Taylor G, Poonia B, Shah A, Bagchi S. Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review. Clin Cardiol 2020;43:222-34. [PMID: 31785111 DOI: 10.1002/clc.23299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
42 Chen CH, Lin CL, Kao CH. Relation Between Hepatitis C Virus Exposure and Risk of Osteoporosis: A Nationwide Population-Based Study. Medicine (Baltimore) 2015;94:e2086. [PMID: 26632720 DOI: 10.1097/MD.0000000000002086] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
43 Nagano T, Seki N, Tomita Y, Sugita T, Aida Y, Itagaki M, Sutoh S, Abe H, Tsubota A, Aizawa Y. Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions. Int J Mol Sci 2015;16:20576-94. [PMID: 26334270 DOI: 10.3390/ijms160920576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
44 Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67:2025-2034. [PMID: 29703790 DOI: 10.1136/gutjnl-2018-316234] [Cited by in Crossref: 70] [Cited by in F6Publishing: 54] [Article Influence: 23.3] [Reference Citation Analysis]
45 Wójcik K, Piekarska A, Dąbrowicz A, Stasiak M, Gawryś K, Jabłonowska E. Hepatic Expression of Phosphorylated Kinase Akt and Glycogen Synthase Kinase-3 Isoforms in Patients with Chronic Hepatitis C. Viral Immunol 2019;32:179-85. [PMID: 31091179 DOI: 10.1089/vim.2018.0141] [Reference Citation Analysis]
46 Simon KG, Serfert Y, Buggisch P, Mauss S, Boeker KHW, Klinker H, Müller T, Merle U, Hüppe D, Manns MP, Wedemeyer H. [Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries]. Z Gastroenterol 2021;59:241-9. [PMID: 33684956 DOI: 10.1055/a-1332-2214] [Reference Citation Analysis]
47 Moreira RC, Pacheco AG, Paula A, Cardoso SW, Moreira RI, Ribeiro SR, Nunes EP, Guimarães MR, Mello FC, Veloso VG, Grinsztejn B. Diabetes Mellitus is Associated with Increased Death Rates Among HIV-Infected Patients in Rio de Janeiro, Brazil. AIDS Res Hum Retroviruses 2016;32:1210-8. [PMID: 27329066 DOI: 10.1089/AID.2015.0265] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
48 Tu T, Bühler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem 2017;398:817-37. [PMID: 28455951 DOI: 10.1515/hsz-2017-0118] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
49 Ding Y, Li G, Zhou Z, Deng T. Molecular mechanisms underlying hepatitis C virus infection-related diabetes. Metabolism 2021;121:154802. [PMID: 34090869 DOI: 10.1016/j.metabol.2021.154802] [Reference Citation Analysis]
50 Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E, Fassio G, Bianco Mauthe Degerfeld AGF, Gallo M, Giordanino C, Terzi di Bergamo L, Ribaldone D, Bugianesi E, Smedile A, Rizzetto M, Saracco GM. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol 2018;90:320-7. [DOI: 10.1002/jmv.24954] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
51 Kralj D, Virović Jukić L, Stojsavljević S, Duvnjak M, Smolić M, Čurčić IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol 2016;4:66-75. [PMID: 27047774 DOI: 10.14218/JCTH.2015.00051] [Cited by in Crossref: 46] [Cited by in F6Publishing: 26] [Article Influence: 9.2] [Reference Citation Analysis]
52 Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? Digestive and Liver Disease 2016;48:105-11. [DOI: 10.1016/j.dld.2015.10.016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
53 Tamaki N, Kurosaki M, Yasui Y, Tsuchiya K, Izumi N. Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. J Med Ultrason (2001) 2021. [PMID: 34165645 DOI: 10.1007/s10396-021-01103-4] [Reference Citation Analysis]
54 Li Z, Li Y, Bi Y, Zhang H, Yao Y, Li Q, Cun W, Dong S. Extracellular Interactions between Hepatitis C Virus and Secreted Apolipoprotein E. J Virol 2017;91:e02227-16. [PMID: 28539442 DOI: 10.1128/JVI.02227-16] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
55 Lee KK, Stelzle D, Bing R, Anwar M, Strachan F, Bashir S, Newby DE, Shah JS, Chung MH, Bloomfield GS, Longenecker CT, Bagchi S, Kottilil S, Blach S, Razavi H, Mills PR, Mills NL, McAllister DA, Shah ASV. Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. Lancet Gastroenterol Hepatol 2019;4:794-804. [PMID: 31377134 DOI: 10.1016/S2468-1253(19)30227-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 14.5] [Reference Citation Analysis]
56 Wang Y, Hou J. Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools. Hepatol Int 2016;10:448-61. [DOI: 10.1007/s12072-015-9695-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
57 Badawi A, Di Giuseppe G, Arora P. Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017). PLoS One 2018;13:e0208839. [PMID: 30540839 DOI: 10.1371/journal.pone.0208839] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
58 Zhao Y, Xing H. A Different Perspective for Management of Diabetes Mellitus: Controlling Viral Liver Diseases. J Diabetes Res 2017;2017:5625371. [PMID: 28352640 DOI: 10.1155/2017/5625371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
59 Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-brandt L, Negro F; on behalf of the BOSTIC Study Group. Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. J Viral Hepat 2018;25:920-9. [DOI: 10.1111/jvh.12891] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
60 Sigon G, D'Ambrosio R, Clerici M, Pisano G, Chantarangkul V, Sollazzi R, Lombardi R, Peyvandi F, Lampertico P, Fargion S, Tripodi A, Fracanzani AL. Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. Liver Int 2019;39:2309-16. [PMID: 31419372 DOI: 10.1111/liv.14213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
61 Yair-Sabag S, Nussinson E, Ben-Assuli O, Shibli F, Shahbari A, Zelber-Sagi S. Retrospective study of the associations between hepatitis C virus infection and metabolic factors. World J Hepatol. 2016;8:1269-1278. [PMID: 27843537 DOI: 10.4254/wjh.v8.i30.1269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
62 Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. J Clin Med. 2020;9. [PMID: 32092892 DOI: 10.3390/jcm9020563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
63 Cooper CL, Galanakis C, Donelle J, Kwong J, Boyd R, Boucher L, Kendall CE. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis 2019;19:712. [PMID: 31438873 DOI: 10.1186/s12879-019-4315-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
64 Thuluvath PJ, Savva Y. Mental and physical health-related quality of life in patients with hepatitis C is related to baseline comorbidities and improves only marginally with hepatitis C cure. Clin Transl Gastroenterol 2018;9:149. [PMID: 29691379 DOI: 10.1038/s41424-018-0016-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
65 Cai H, Yao W, Huang J, Xiao J, Chen W, Hu L, Mai R, Liang M, Chen D, Jiang N, Zhou L, Peng T. Apolipoprotein M, identified as a novel hepatitis C virus (HCV) particle associated protein, contributes to HCV assembly and interacts with E2 protein. Antiviral Res. 2020;177:104756. [PMID: 32119870 DOI: 10.1016/j.antiviral.2020.104756] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 Meoni G, Lorini S, Monti M, Madia F, Corti G, Luchinat C, Zignego AL, Tenori L, Gragnani L. The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy. Sci Rep. 2019;9:4128. [PMID: 30858406 DOI: 10.1038/s41598-019-40028-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
67 Cacciola I, Borgia F, Filomia R, Pitrone C, Franzè MS, Alibrandi A, Squadrito G, Guarneri C, Papaianni V, Cannavò SP, Raimondo G. Outcome of cutaneous psoriasis in hepatitis C virus-infected patients treated with Direct-Acting Antiviral therapy. J Viral Hepat 2020;27:333-7. [PMID: 31698529 DOI: 10.1111/jvh.13230] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
68 Andrade VG, Yamashiro FDS, Oliveira CV, Moreira A, Winckler FC, Silva GF. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES. Arq Gastroenterol 2018;55:274-8. [PMID: 30540091 DOI: 10.1590/S0004-2803.201800000-69] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
69 Ward T, Gordon J, Jones B, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P. Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease. Clin Drug Investig 2017;37:61-70. [PMID: 27587071 DOI: 10.1007/s40261-016-0458-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
70 Sliem HA, Salem AS, Hussien WM, El Sayed HRA. Arterial wall structural changes in noncirrhotic chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2019;31:1432-8. [PMID: 31569123 DOI: 10.1097/MEG.0000000000001429] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Saleh M, Rüschenbaum S, Welsch C, Zeuzem S, Moradpour D, Gouttenoire J, Lange CM. Glycogen Synthase Kinase 3β Enhances Hepatitis C Virus Replication by Supporting miR-122. Front Microbiol 2018;9:2949. [PMID: 30542341 DOI: 10.3389/fmicb.2018.02949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
72 Milano M, Aghemo A, Mancina RM, Fischer J, Dongiovanni P, De Nicola S, Fracanzani AL, D’Ambrosio R, Maggioni M, De Francesco R. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology. 2015;62:111-117. [PMID: 25820484 DOI: 10.1002/hep.27811] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
73 Ichikawa T, Miyaaki H, Miuma S, Taura N, Motoyoshi Y, Akahoshi H, Nakamura J, Takahashi Y, Honda T, Yajima H, Uehara R, Hino N, Narita S, Tanaka H, Sasaki S, Nakao K. Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir. Biomed Rep 2019;10:156-64. [PMID: 30906544 DOI: 10.3892/br.2019.1189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
74 Lichtenstein KA, Hart RL, Wood KC, Bozzette S, Buchacz K, Brooks JT; HIV Outpatient Study Investigators. Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2015;69:306-11. [PMID: 26181706 DOI: 10.1097/QAI.0000000000000581] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
75 Lassen S, Grüttner C, Nguyen-Dinh V, Herker E. Perilipin-2 is critical for efficient lipoprotein and hepatitis C virus particle production. J Cell Sci 2019;132:jcs217042. [PMID: 30559250 DOI: 10.1242/jcs.217042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
76 Jarcuska P, Abdel-Razik A, Flisiak R, Singh RB. Chronic Viral Hepatitis and Metabolic Syndrome/Cardiovascular Risk. Can J Gastroenterol Hepatol 2018;2018:7369314. [PMID: 30519548 DOI: 10.1155/2018/7369314] [Reference Citation Analysis]
77 Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S. Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review. J Clin Transl Hepatol. 2017;5:343-362. [PMID: 29226101 DOI: 10.14218/jcth.2017.00021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
78 Retamozo S, Brito-Zerón P, Quartuccio L, De Vita S, Ramos-Casals M. Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection. Expert Rev Clin Pharmacol 2017;10:1085-101. [PMID: 28715943 DOI: 10.1080/17512433.2017.1357466] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
79 Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, Primorac D, Vceva A, Wu GY, Smolic M. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front Pharmacol 2021;12:678546. [PMID: 34045969 DOI: 10.3389/fphar.2021.678546] [Reference Citation Analysis]
80 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22:9674-9693. [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 57] [Article Influence: 16.3] [Reference Citation Analysis]
81 Peláez-Jaramillo MJ, Cárdenas-Mojica AA, Gaete PV, Mendivil CO. Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. Diabetes Ther 2018;9:521-43. [PMID: 29411291 DOI: 10.1007/s13300-018-0374-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
82 Bassendine MF, Nielsen SU, Bridge SH, Felmlee DJ, Sheridan DA, Packard CJ, Neely RD. Hepatitis C virus and atherosclerosis: A legacy after virologic cure? Clin Res Hepatol Gastroenterol 2017;41:25-30. [PMID: 27840032 DOI: 10.1016/j.clinre.2016.09.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]